The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet.

Expert Opinion on Investigational Drugs
Christophe Marchand

Abstract

Anti-HIV combination therapies in a single formulation currently target only HIV-1 reverse transcriptase via two different mechanisms of action by associating a nucleoside and a non-nucleoside reverse transcriptase inhibitor. These combination therapies are therefore referred to as multi-class combination products. The elvitegravir Quad pill (Gilead Sciences), when approved by the Food and Drug Administration for the treatment of HIV/AIDS, will become the first once-daily dual-target anti-HIV tablet. This "4 in 1" tablet targets HIV-1 integrase by elvitegravir boosted by the pharmaco-enhancer cobicistat and HIV-1 reverse transcriptase by the two nucleoside reverse transcriptase inhibitors emtricitabine + tenofovir disoproxil fumarate. A second pill referred to as the 572-Trii pill (Shionogi-ViiV Healthcare, LLC), also based on the dual inhibition of integrase and reverse transcriptase, is currently in late-phase clinical trials. The availability of these novel once-daily anti-HIV tablets will improve treatment adherence and offer new perspective for patient failing existing antiviral regimens.

References

Aug 4, 2009·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Martin MarkowitzUNKNOWN Protocol 004 Part II Study Team
Feb 2, 2010·Nature·Stephen HarePeter Cherepanov
Dec 17, 2011·Nature Reviews. Drug Discovery·Yves Pommier, Christophe Marchand
Feb 15, 2012·The Pediatric Infectious Disease Journal·Verónica BrizMa Ángeles Muñoz-Fernández

❮ Previous
Next ❯

Citations

Aug 8, 2013·Journal of Medicinal Chemistry·Jens-Uwe Peters
Aug 14, 2013·Retrovirology·Soundasse MunirOlivier Delelis
Jul 23, 2013·Viruses·Md Alamgir HossainCha-Gyun Shin
Aug 2, 2012·Expert Opinion on Pharmacotherapy·Rik Schrijvers, Zeger Debyser
Oct 25, 2014·Viruses·Pinar Iyidogan, Karen S Anderson
Dec 18, 2012·Current Opinion in Infectious Diseases·Peter K QuashieMark A Wainberg
May 7, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Ole J BjerrumHarrie C M Boonen
Nov 12, 2013·Journal of Chemical Information and Modeling·Qi ChenDongqing Wei
Jun 6, 2014·ACS Medicinal Chemistry Letters·Muriel BillambozPhilippe Cotelle
Oct 15, 2014·International Journal of STD & AIDS·Asma Khatri, Marion J Skalweit
Jan 27, 2017·Frontiers in Microbiology·Eloïse ThierryOlivier Delelis
Dec 12, 2013·Journal of Acquired Immune Deficiency Syndromes : JAIDS·David B HannaRobert C Kaplan
Jun 12, 2014·Journal of Medicinal Chemistry·Major GooyitKim D Janda

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.